Two Transgenic Mouse Facilities are available to OSUCCC members. OSUCCC intends to supplement existing facilities at the OSU Biotechnology Center (OSUBC) and the Children's Hospital Research Foundation (CHRF) to increase their capacity to meet the requirements of Cancer Center members for transgenic animals. This avoids the substantial additional costs and the duplication of effort of establishing a third transgenic animal facility. The state-of-the-art OSUBC facility produces transgenic mice by pronuclear injection. It also creates embryonic stem (ES) cell lines and chimeric animals derived from these lines. The current size of the facility is sufficient to house approximately 2,000 mice. It is anticipated that by late summer of 1995, the facility will have completed an expansion into neighboring Pressey Hall which will increase the capacity of the Facility to 10,000 mice. The CHRF Transgenic Facility is located on the lower level of the Wexner Institute for Pediatric Research. This facility has two dedicated animal rooms and one procedure room with a total capacity of approximately 2,000 animals. The facility is equipped with state-of-the-art environmental controls, surgical instruments, and monitoring equipment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-22
Application #
5206778
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
22
Fiscal Year
1996
Total Cost
Indirect Cost
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications